Last Updated : September 6, 2024
Details
FilesGeneric Name:
tarlatamab
Project Status:
Active
Therapeutic Area:
Extensive stage small cell lung cancer
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0351-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult
patients with extensive stage small cell lung cancer (ES-SCLC) with disease
progression on or after at least two prior lines of therapy including
platinum-based chemotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 03-Jul-24 |
|---|---|
| Call for patient/clinician input closed | 23-Aug-24 |
| Submission received | 14-Aug-24 |
| Submission accepted | 28-Aug-24 |
| Review initiated | 29-Aug-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 15-Nov-24 |
| Deadline for sponsors comments | 26-Nov-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 19-Dec-24 |
| Expert committee meeting (initial) | 08-Jan-25 |
| Draft recommendation issued to sponsor | January 20, 2025 To January 22, 2025 |
| Draft recommendation posted for stakeholder feedback | 30-Jan-25 |
| End of feedback period | 13-Feb-25 |
Files
Last Updated : September 6, 2024